BMS sale de compras...

Bristol-Myers Squibb Co. (BMY) is looking to acquire either privately held biotechnology companies or those worth about $1 billion following initial public stock offerings, the drug maker's leader said Tuesday.

Chief Executive James Cornelius told shareholders at the drug maker's annual meeting Tuesday in Plainsboro, N.J., that Bristol-Myers hoped to gain some of the benefits of a large-scale acquisition "without spending tens of billions of dollars" as some of its larger rivals have.